-
Highlights from ESPE-ESE 2025 Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-06-12 Claire Greenhill
May 2025 marked the inaugural joint meeting of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE), bringing adult and paediatric endocrinologists together under the theme of ‘connecting endocrinology across the life course’. Around 8,000 people convened in Copenhagen, Denmark, for an exciting and wide-ranging programme across 4 days. The first lecture
-
Tirzepatide differentially affects body weight in mice and humans Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-06-09 Aaron Novikoff, Timo D. Müller
Advances in biomedical research often result from a straightforward formula: a good working hypothesis, a set of dedicated investigators, and access to calorimetric chambers and a laboratory scale. The success of this approach has again been demonstrated in a new Cell Metabolism report showing that tirzepatide induces weight loss through partially distinct mechanisms in mice and humans.
-
Diabetes mellitus and the key role of endoplasmic reticulum stress in pancreatic β cells Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-06-04 Maria Lytrivi, Yue Tong, Enrico Virgilio, Xiaoyan Yi, Miriam Cnop
-
Muscle mass loss during GLP1 receptor agonist therapy prevented with GDF8 and activin A blockade Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-06-04 Olivia Tysoe
GLP1 receptor agonist therapies induce substantial weight loss, but up to 40% of this weight loss is lean mass, particularly muscle. Loss of muscle mass can be caused via activation of type II activin receptors ActRIIA and/or ActRIIB, and blockade of these receptors can lead to muscle growth in humans. A study in Nature Communications describes a strategy for preventing muscle mass loss during GLP1
-
Diabetes mellitus polygenic risk scores: heterogeneity and clinical translation Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-06-04 Hector I. Ortega, Miriam S. Udler, Anna L. Gloyn, Seth A. Sharp
-
Hyperglycaemia increases anxiety in mice by boosting neuronal CCL2 Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-06-02 Senegal Carty
People with diabetes mellitus experience elevated levels of stress. Learning whether dysglycaemia contributes to this effect by affecting neuronal signalling could help develop treatments that reduce anxiety in people with diabetes mellitus. A new study published in Nature Metabolism reports that in a mouse model of diabetes mellitus, increased expression of the pro-inflammatory chemokine CCL2 in neurons
-
Hypoglycaemia exacerbates diabetic retinopathy via HIF accumulation Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-05-23 Olivia Tysoe
Tight glycaemic control (TGC) is known to reduce the risk and/or progression of diabetic retinopathy, a diabetes mellitus complication that causes the breakdown of the inner blood–retinal barrier (iBRB), leading to vision loss. However, intensive TGC in the early stages of diabetic retinopathy can lead to a worsening of the condition. Building on the authors’ previous work, a study in Science Translational
-
Endocrine-disrupting chemicals and female reproductive health: a growing concern Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-05-22 Anne-Simone Parent, Pauliina Damdimopoulou, Hanna K. L. Johansson, Nora Bouftas, Monica K. Draskau, Delphine Franssen, Julie Fudvoye, Majorie van Duursen, Terje Svingen
-
The endocrine effects of leptin on energy metabolism Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-05-22 Rugivan Sabaratnam
The second law of thermodynamics asserts that energy within a system must be conserved, and that changes arise from alterations in energy input or output. In obesity, this principle implies that changes in body weight, where energy is stored as triglycerides in adipose tissue, result from alterations in energy intake or expenditure. To maintain a stable body weight, energy intake must balance energy
-
The inflammatory spark: how TNF rewrote the insulin resistance narrative Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-05-16 Subhajit Dutta
Long before the word ‘inflammation’ gained prominence in immunometabolic research, Gökhan S. Hotamışlıgil and his team were investigating the molecular mechanism of a key inflammatory player, tumour necrosis factor (TNF), which drives obesity-induced insulin resistance. In the 1990s, obesity was primarily viewed as a consequence of an imbalance between caloric intake and energy expenditure, and was
-
Liothyronine treatment for hypothyroidism — a patient’s view Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-05-15 Mary Saunders
Despite its prevalence, treatment of hypothyroidism has long divided opinion in the research and clinical fields. Here, I share my experience as a patient living with hypothyroidism for 16 years, as well as the difficulties I have faced in achieving consistent and effective treatment tailored to my individual needs.
-
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-05-13 Christopher S. Walker, Jacqueline F. Aitken, Greeshma Vazhoor Amarsingh, Shaoping Zhang, Garth J. S. Cooper
-
The incretin effect — almost magical Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-05-07 Rasmus Syberg Rasmussen, Lærke Smidt Gasbjerg
The foundations for modern medical treatments for diabetes mellitus and obesity were laid more than 60 years ago by several scientific groups in London. Importantly, the 1965 publication of Intestinal factors in the control of insulin secretion by McIntyre and colleagues investigated both glucose metabolism and the role of the liver. This work contributed markedly to the discovery of the incretin effect
-
Individualized and innovative gender healthcare for transgender and nonbinary youth Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-05-07 Drew B. A. Clark, Daniel L. Metzger, Ken C. Pang, Colton St. Amand, Karine Khatchadourian
Increasing numbers of transgender and nonbinary youth are now accessing gender-affirming medical interventions, which have been demonstrated to improve health and well-being. This Perspective addresses how the needs of transgender and nonbinary youth, up to age 18, can be addressed through individualized gender-embodiment care. We first review standard medical therapies, including gonadotropin-releasing
-
Prolactin regulates body temperature in pregnancy Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-05-07 Claire Greenhill
Prolactin is known to have a wide range of functions during reproduction, from supporting lactation to initiating maternal behaviours. New research now indicates that prolactin also has a role in regulating body temperature during pregnancy in mice. The study involved mice with adenovirus-Cre deletion of the gene that encodes prolactin receptor (Prlr) in the preoptic area and mice with conditional
-
Promising drugs for PCOS: targeting metabolic and endocrine dysfunctions Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-05-06 Kaipeng Zhou, Chen Lou, Po-Han Chang, Jingjing Jiang, Yue Zhao, Hsun-Ming Chang, Liangshan Mu
-
Publisher Correction: Neuro–immuno–endocrinology of the skin: how environment regulates body homeostasis Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-05-02 Radomir M. Slominski, Chander Raman, Anton M. Jetten, Andrzej T. Slominski
Correction to: Nature Reviews Endocrinology https://doi.org/10.1038/s41574-025-01107-x, published online 22 April 2025.
-
Reply to ‘Ensuring diverse representation and minimizing conflicts of interest in clinical practice guidelines’ Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-05-01 Ravi Savarirayan, Svein Otto Fredwall
Thank you for your thoughtful letter (Schelhaas, A. et al. Ensuring diverse representation and minimizing conflicts of interest in clinical practice guidelines. Nat. Rev. Endocrinol. https://doi.org/10.1038/s41574-025-01122-y (2025))1 concerning the recent guidelines regarding the implementation and monitoring of vosoritide therapy in individuals with achondroplasia (Savarirayan, R. et al. International
-
Ensuring diverse representation and minimizing conflicts of interest in clinical practice guidelines Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-05-01 Andrea Schelhaas, Kara Ayers, Stephanie Meredith, Leah Smith, Katie Stoll
During their Q3 2024 investor call, BioMarin, a manufacturer of vosoritide, estimated that 24,000 individuals worldwide could use vosoritide and stated that “new global guidelines” would recommend that “children with achondroplasia be referred as soon as diagnosis is suspected to enable early initiation of treatment”1. In January 2025, a Consensus Statement on the use of vosoritide in achondroplasia
-
Replacing body mass index with relative fat mass to accurately estimate adiposity Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-05-01 Navin Suthahar, Richard N. Bergman, Rudolf A. de Boer
Body mass index (BMI), as its name indicates, is a marker of total body mass and not a specific marker of adipose tissue mass. Here, we position relative fat mass (RFM) as an ideal alternative to BMI by highlighting the superior performance of RFM in assessing cardiometabolic risk.
-
A modified liver enzyme with enhanced stability helps to control glycaemia Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-04-22 Senegal Carty
Reducing insulin resistance in skeletal muscle is a promising potential strategy for controlling blood levels of glucose in people with type 2 diabetes mellitus (T2DM). A study published in Diabetologia now shows that treatment with HEXA–Fc (a protein created by fusing the liver enzyme hexosaminidase A (HEXA) with the fragment crystallizable (Fc) region of immunoglobulin G1) can promote glucose uptake
-
Neuro–immuno–endocrinology of the skin: how environment regulates body homeostasis Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-04-22 Radomir M. Slominski, Raman Chander, Anton M. Jetten, Andrzej T. Slominski
-
Potential downsides of calorie restriction Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-04-17 Anyongqi Wang, John Roger Speakman
-
Insulin resistance in type 2 diabetes mellitus Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-04-17 Domenico Accili, Zhaobing Deng, Qingli Liu
-
Older people with type 1 diabetes mellitus: a call for a new management approach Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-04-14 Giuseppe Maltese, Alan J. Sinclair
-
Author Correction: Adrenocortical stem cells in health and disease Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-04-11 Yulan Chu, Jordan Setayesh, Typhanie Dumontet, Lauren Krumeich, Johanna Werner, Isabele F. Moretti, Kelly De Sousa, Christopher Kennedy, Christopher La Pensee, Antonio M. Lerario, Gary D. Hammer
Correction to: Nature Reviews Endocrinology https://doi.org/10.1038/s41574-025-01091-2, published online 10 March 2025.
-
mTORC1 is the central regulator in pancreatic β-cells Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-04-09 Pei Xu
Mammalian target of rapamycin (mTOR; also termed mechanistic target of rapamycin) is a conserved serine–threonine kinase and forms two large protein complexes (mTOR complexes 1 and 2 (mTORC1 and mTORC2)). The function of mTORC2 is not well understood, but mTORC1 is well known as the central metabolic regulator in cells. mTORC1 integrates and coordinates a cell’s response to signals from intracellular
-
Highlights from SfE BES 2025 Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-04-07 Olivia Tysoe
This March, more than 1,000 endocrinologists convened in Harrogate, UK, for the annual meeting of the Society for Endocrinology (SfE BES). For the opening session, Marie Freel (Queen Elizabeth University Hospital, Glasgow, UK) and Karen Forbes (University of Leeds, UK) highlighted key advances in clinical and basic endocrinology from the past year, and discussed future challenges. Highlights included
-
JNK at the helm: decoding obesity-driven insulin resistance Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-04-07 Subhajit Dutta
Back in the early 2000s, obesity was known to be a major risk factor for type 2 diabetes mellitus (T2DM), but the intricate molecular mechanisms that link these two metabolic conditions remained unclear. Obesity was evidently associated with chronic inflammation and insulin resistance, but how these processes intertwined at the molecular level was still a mystery. Why did obesity trigger insulin resistance
-
Empowering early career researchers: academy-driven pathways to excellence Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-04-07 Nils J. Færgeman, Tore S. B. Christiansen, Gretchen Repasky
-
Gut microbial metabolites protect against obesity Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-04-04 Katrin Legg
Studies in rodents and humans have established a relationship between the gut microbiome and obesity, but how our gut residents might promote or inhibit weight gain is less well defined. A paper in Nature Metabolism has now shown that certain microbial metabolites confer an anti-obesity effect in mice by modulating the intestinal immune response of the host. The authors identified an association between
-
Gut instincts — the origins of the incretin effect Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-04-03 Sinéad Cadogan
The intricate relationship between the gut and pancreatic function has long intrigued researchers. As early as 1929, Zunz and LaBarre proposed the existence of an ‘incretin’ (that is, a gut-derived factor that could enhance insulin secretion) on the basis of cross-circulation experiments in dogs. However, their hypothesis remained speculative for decades, as research was hindered by the lack of tools
-
Progesterone in pregnancy Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-03-31 Claire Greenhill
Maternal sex steroid hormones (such as oestrogen and progesterone) are known to have important roles in reproduction, contributing to maintaining pregnancy and to embryonic development. However, how maternal progesterone might influence the embryo and the maternal metabolism has been unclear; a new study set out to investigate this question. The researchers focused on membrane progesterone receptor
-
A new model predicts the best medication for patients with type 2 diabetes mellitus Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-03-26 Olivia Tysoe
Many glucose-lowering medications for type 2 diabetes mellitus (T2DM) have varying levels of efficacy in different patients, but it is currently not well understood which criteria should be used to personalize T2DM treatment. A study published in The Lancet has developed a model to predict the efficacy of different T2DM drug classes in reducing glycaemia in patients, based on routinely recorded clinical
-
Steroid hormones as modulators of anti-tumoural immunity Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-03-24 Paul Schwarzlmueller, Alexandra Triebig, Guillaume Assié, Anne Jouinot, Sebastian Theurich, Tanja Maier, Felix Beuschlein, Sebastian Kobold, Matthias Kroiss
-
A novel anti-obesity peptide that targets the hypothalamus Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-03-24 Senegal Carty
Computational tools that predict which amino acid sequences are produced by cleavage enzymes can accelerate the discovery of bioactive peptides with therapeutic potential. A study recently published in Nature presents a peptide prediction programme that was used to search for novel anti-obesity peptides made by prohormone convertase enzymes (also known as proprotein convertase subtilisin/kexin (PCSK)
-
Mitigating the environmental effects of healthcare: the role of the endocrinologist Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-03-13 Chantelle Rizan, Jeanette M. Rotchell, Pei Chia Eng, Bernard Robaire, Corina Ciocan, Nitin Kapoor, Sanjay Kalra, Jodi D. Sherman
-
Adrenocortical stem cells in health and disease Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-03-10 Yulan Chu, Jordan Setayesh, Typhanie Dumontet, Lauren Krumeich, Johanna Werner, Isabele F. Moretti, Kelly De Sousa, Christopher Kennedy, Christopher La Pensee, Antonio M. Lerario, Gary D. Hammer
-
Leptin–thyroid hormone axis affects energy use in muscle Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-03-10 Claire Greenhill
Thyroid hormones have a wide range of functions, including regulating energy metabolism. In a study published in Cell Metabolism, a group of researchers show that leptin is involved in thyroid hormone activation, which results in an increased metabolic rate in the context of obesity. In mice, leptin injection increased the expression of type 2 deiodinase mRNA. Of note, this effect was not seen in db/db
-
Islet hormones at the intersection of glucose and amino acid metabolism Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-03-07 Phillip J. White, Nicolai J. Wewer Albrechtsen, Jonathan E. Campbell
-
How the WHIMS clinical trial shaped the future of women’s health research Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-03-05 Phaedra R. Keller-Norrell
In 1993, the 103rd United States Congress signed the NIH Revitalization Act into law; prior to this date, women (and members of minority groups) were largely excluded from clinical trials. To this day, women experience more adverse reactions to medication and surgical complications involving medical device implants than men, as the studies regarding the safety and efficacy of medications and devices
-
Anti-PIT1 hypophysitis after immune checkpoint inhibitor treatment Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-02-27 Shin Urai, Genzo Iguchi, Yutaka Takahashi
-
Obesity induces systemic insulin resistance via endothelium-specific insulin receptor inhibition Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-02-26 Olivia Tysoe
Insulin resistance is a key component of the pathogenesis and progression of obesity-associated type 2 diabetes mellitus (T2DM). The insulin receptor is expressed in endothelial cells and insulin acts on blood vessels to increase blood flow to metabolic tissues. Endothelial insulin resistance was already known to be reduced in people with T2DM compared with healthy individuals, but the mechanisms of
-
Bone and muscle crosstalk in ageing and disease Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-02-26 Ben Kirk, Giovanni Lombardi, Gustavo Duque
-
Sexual dimorphism in pituitary neuroendocrine tumours Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-02-25 Shaojian Lin, Jun Li, Zhe Bao Wu
Pituitary neuroendocrine tumours (PitNETs) exhibit notable sex-related differences, particularly in prolactinomas and corticotroph tumours. Findings from the past 5 years in other cancers suggest that interactions between sex hormones and the immune system, as well as epigenetic modifications specific to sex chromosomes, could influence sex differences in tumour development.
-
Neutrophils might link intestinal damage to retinopathy in type 2 diabetes mellitus Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-02-24 Senegal Carty
Type 2 diabetes mellitus (T2DM) is associated with retinopathy, which can cause vision loss. A new study suggests that damage to the intestinal lining caused by neutrophil extracellular traps (NETs) might promote retinopathy in people with T2DM by releasing antigens from the gut into the blood and causing systemic inflammation. The researchers then investigated whether inhibiting NETosis (NET release)
-
Engineering adipocytes for cancer treatment Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-02-20 Claire Greenhill
Tumour cells are well known to have an altered metabolic profile and are more able to obtain and metabolize nutrients than surrounding cells. Several existing cancer therapies target tumour metabolism. A new study in Nature Biotechnology reports the development of a cell-based therapy using engineered adipocytes to reduce tumour cell growth by altering tumour metabolism. The researchers used CRISPR
-
The enduring relevance of the Randle cycle Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-02-19 Azariyas A. Challa
In people with diabetes mellitus, the heart is metabolically characterized by the excessive use of fatty acids and diminished oxidation of glucose. These changes are implicated in decreased cardiac efficiency, vulnerability to ischaemic insults and an increased risk of heart failure. Interestingly, these alterations have been observed even in the absence of any impairments in cardiac insulin signalling
-
The study that pioneered islet isolation techniques Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-02-18 Rula Bany Bakar
In rodents, the endocrine pancreas consists of islets of Langerhans scattered throughout the exocrine acinar tissue and accounts for a minor fraction of the organ’s total volume. This anatomical configuration, combined with the small size of the islets and the fact that they are embedded within enzyme-rich exocrine tissue, has historically made isolating intact and functional islets a considerable
-
Tryptophan metabolism, exercise and depression Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-02-11 Brandon A. Yates
Depression is linked to an altered stress response, as measured by elevated levels of cortisol and systemic inflammation. Many individuals become resistant to pharmacological treatments; however, non-pharmacological treatments, such as increased physical activity and exercise training, can reduce symptoms of depression in some patients. A decade ago, a key paper helped to define the mechanisms that
-
Recent advances in treatments for congenital adrenal hyperplasia Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-02-11 Henrik Falhammar, Svetlana Lajic, Anna Nordenström
The first CRFR1 antagonist (crinecerfont) to be used for the treatment of congenital adrenal hyperplasia recently received FDA approval. This Clinical Outlook discusses the latest phase III studies in children and adults, as well as how crinecerfont — in combination with glucocorticoid replacement — might change clinical practice and affect long-term co-morbidities.
-
Hypoparathyroidism: diagnosis, management and emerging therapies Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-02-04 Sarah Khan, Aliya A. Khan
-
Exercise exacerbates cardiac damage from high-fat, high-calorie feeding in mice Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-01-29 Olivia Tysoe
Physical exercise is well known to help to prevent obesity and to benefit cardiometabolic health. A new study in Nature Communications aimed to determine whether physical exercise could reverse cardiac dysfunction caused by a high-fat, high-calorie (HFHC) diet. “We originally wanted to observe a possible cardioprotective effect of physical exercise in HFHC-fed mice,” explains corresponding author Lang
-
The effects of type 1 and type 2 diabetes mellitus on bone health in chronic kidney disease Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-01-16 Jasna Aleksova, Peter Ebeling, Grahame Elder
-
Exploring the functions of the myokine feimin Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-01-15 Claire Greenhill
Skeletal muscle produces a range of myokines, which have various effects throughout the body. Two new studies published in Nature Metabolism have identified a myokine that they have termed feimin, and characterized its effects on glucose homeostasis and exercise performance. Using mice with whole-body knockout of the gene encoding feimin or one of various organ-specific knockout models (for example
-
Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-01-09 Shintaro Iwama, Tomoko Kobayashi, Hiroshi Arima
-
Metabolic effects of gender-affirming hormone therapy Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-01-08 Senegal Carty
As the field of gender-affirming hormone therapy (GAHT) evolves, research into how this type of treatment affects metabolism is needed to continually improve healthcare for transgender individuals. Twenty transgender men and 15 transgender women participated in the study. GAHT was administered independently of the study, so there was variation in the treatment regimens within each group. Before GAHT
-
Illuminating the metabolic effects of circadian misalignment Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-01-06 Ioannis G. Lempesis
Circadian misalignment affects physiology and metabolism and increases the risk of developing cardiometabolic disease. A pivotal study by Frank Scheer’s team provided clear evidence that misaligned sleep–wake cycles and fasting–eating cycles impair glucose tolerance, insulin sensitivity and blood pressure, highlighting the importance of synchronizing lifestyles with our internal biological clocks.
-
Enhancing adipose tissue plasticity: progenitor cell roles in metabolic health Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-01-06 Simon Lecoutre, Clémentine Rebière, Salwan Maqdasy, Mélanie Lambert, Sébastien Dussaud, Jimon Boniface Abatan, Isabelle Dugail, Emmanuel L. Gautier, Karine Clément, Geneviève Marcelin
-
Bile acid metabolism in type 2 diabetes mellitus Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2025-01-06 Marti Cadena Sandoval, Rebecca A. Haeusler